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Research
AbstrACt
Objective To investigate women’s values and preferences 
regarding antiretroviral therapy (ART) during pregnancy to 
inform a BMJ Rapid Recommendation.
setting Primary studies reporting patient-reported 
outcomes relevant to decision-making regarding ART in 
any clinical and geographical setting.
Participants Women living with HIV who are pregnant, 
postpartum or considering pregnancy.
Outcome measures Quantitative measurements and 
qualitative descriptions of values and preferences in 
relation to ART during pregnancy. We also included 
studies on women’s reported barriers and facilitators to 
adherence. We excluded studies correlating objective 
measures (eg, CD4 count) with adherence, or reporting 
only outcomes which are not expected to differ between 
ART alternatives (eg, access to services, knowledge about 
ART).
results We included 15 qualitative studies reporting 
values and preferences about ART in the peripartum 
period; no study directly studied choice of ART therapy 
during pregnancy. Six themes emerged: a desire to reduce 
vertical transmission (nine studies), desire for child to be 
healthy (five studies), concern about side effects to the 
child (eight studies), desire for oneself to be healthy (five 
studies), distress about side effect to oneself (10 studies) 
and pill burden (two studies). None of the studies weighed 
the relative importance of these outcomes directly, but 
pill burden/medication complexity appears to be a lower 
priority for most women compared with other factors. 
Overall, the body of evidence was at low risk of bias, with 
minor limitations.
Conclusions Women who are or may become pregnant 
and who are considering ART appear to place a high value 
on both their own and their children’s health. Evidence 
on the relative importance between these values when 
choosing between ART regimens is uncertain. There is 
variability in individual values and preferences among 
women. This highlights the importance of an individualised 
women-centred approach, such as shared decision-
making when choosing between ART alternatives.
trial registration number International Prospective 
Register of Systematic Reviews:CRD42017057157.
IntrOduCtIOn
Antiretroviral therapy (ART) has transformed 
the health of persons living with HIV. HIV 
can now be managed as a chronic and stable 
condition rather than a progressive disease.1 
Clinical practice guidelines currently recom-
mend combination ART (cART), including 
a ‘backbone’ of two nucleoside or nucleo-
tide reverse transcriptase inhibitors (NRTIs) 
with a third antiretroviral for everyone living 
with HIV.2–5 Pregnant women living with HIV 
can experience healthy pregnancies with a 
low risk of vertical transmission (below 1%) 
if they are offered multifaceted strategies, 
including cART.6 Option B+ is a relatively 
new innovation, where women are advised 
to take cART as soon as they test positive and 
to continue for life.7–9 Support for Option 
B+ is not unanimous: some have raised 
concerns about harms of cART to mother 
and infant.10 In addition, there are a number 
strengths and limitations of this study
 ► This is the first systematic synthesis of women-
reported factors important for shared  decision-
making regarding antiretroviral therapy (ART) during 
pregnancy.
 ► Identified themes were consistent with what women 
on the linked Rapid Recommendation guideline 
panel considered most important.
 ► Design and reporting was variable between studies, 
and it is challenging to separate factors that may 
influence the choice of ART regimen—personal, 
community and health service issues are often 
intertwined.
 ► In addition to the relative importance of each factor, 
values and preferences were quite variable between 
women, highlighting the importance of shared 
decision-making.
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of individual, community and health system barriers that 
women, caregivers and healthcare providers experience 
when initiating and adhering to cART during and after 
pregnancy.11–14 Among these, commonly cited barriers 
include stigma, inadequate time to deal with a new diag-
nosis, denial of HIV status, intimate partner violence15 16 
and access to care.11–14
Shared decision-making is a patient-centred approach 
and has been tested in some chronic conditions, 
including HIV.17–19 Influential guidelines have been crit-
icised for emphasising child over maternal health and by 
taking a ‘public health perspective’, thus de-emphasising 
each woman’s autonomy to choose the ART regimen that 
best fits in the particular woman’s context.2 20 Suboptimal 
relationships and communication between healthcare 
providers and women living with HIV have important 
consequences on initiation, adherence and retention 
in antenatal care.11–14 17 Informed discussion between 
women living with HIV and their healthcare providers 
about the benefits and harms of cART is important, 
because values and preferences may differ among women 
and thus influence their decisions to initiate and adhere 
to therapy.
Evidence from a recent randomised controlled trial 
‘Promoting Maternal and Infant Survival Everywhere’ 
suggests that two common cART regimens confer similar 
reduction of vertical transmission risk, but also raised the 
possibility that the most commonly used NRTI backbone, 
tenofovir plus emtricitabine, increases the risk of serious 
adverse pregnancy outcomes compared with zidovudine 
(AZT) plus lamivudine.21 This study triggered a BMJ 
Rapid Recommendation guideline—a BMJ series of trust-
worthy recommendations published in response to poten-
tially practice-changing evidence.22 23 A linked systematic 
review of the available literature found low-to-mod-
erate quality evidence that tenofovir plus emtricitabine 
increases early preterm birth as well as stillbirth and early 
neonatal mortality compared with the AZT plus lamivu-
dine backbone.24 To inform the BMJ Rapid Recommen-
dation on cART regimens in pregnancy, we performed 
this systematic review to explore how women living with 
HIV value possible benefits and harms of ART.
MethOds
We followed the Meta-analysis of Observational Studies 
in Epidemiology (MOOSE) reporting guidelines (see 
online supplementary appendix 1). The study protocol 
is registered in International Prospective Register of 
Systematic Reviews: CRD42017057157 (online supple-
mentary appendix 2).
eligibility criteria
We considered eligible both quantitative and qualitative 
studies from any setting and location, enrolling women 
living with HIV of childbearing age (15–50 years), who 
were diagnosed at any time, that evaluated the initiation, 
adherence or change in ART regimen during pregnancy 
(for any duration, eg, short-course prophylaxis or cART). 
Included studies must have reported on the values and 
preferences of women considering or discussing ART 
during pregnancy. However, women did not have to be 
pregnant at the time of the study. Studies reporting the 
following outcomes were eligible: (1) health state value 
studies, (2) direct choice studies, (3) studies on non-utility 
measurement of health states and (4) qualitative studies 
(eg, focus groups, semistructured interviews). There 
was no language restriction. We focussed exclusively 
on the women’s perspective. We excluded studies that 
reported overall health-related quality of life, non-pri-
mary studies and case reports, analyses of data that are 
not women-reported (eg, database studies), studies on 
use of intrapartum ART only and studies not discussing 
ART. Implementation and equity considerations from a 
societal perspective were not included.
search strategy
We searched MEDLINE, EMBASE and PsycINFO from 
1 January 2000 to 11 February 2017 using a combination 
of keywords and MeSH/EMTREE terms for ‘HIV’ AND 
‘pregnancy’ AND ‘antiretroviral therapy’ (see online 
supplementary appendix 3). We also used a search filter 
for patient values and preferences, including terms 
related to health behaviours, patient values and patient 
preferences.25 We reviewed the references of systematic 
reviews on similar topics11–14 for other potentially eligible 
studies. We searched for grey literature online with 
Google, using the terms ‘HIV’ and ‘pregnant OR preg-
nancy’ and ‘preference OR experience’.
study selection
Title and abstract as well as full-text screening was done 
independently and in duplicate by reviewer pairs (LL, 
MMB, YC). Disagreements were resolved by consensus.
Quality assessment
All eligible studies reported qualitative outcomes. We 
used the Critical Appraisal Skills Programme checklist 
to assess methodological quality of individual qualitative 
studies.26
data collection and presentation
Two reviewers independently and in duplicate extracted 
data using a standardised spreadsheet in Microsoft Excel. 
The following details were extracted: first author, publi-
cation year, number of participants, participant demo-
graphics (eg, age, length of time living with HIV, whether 
they have previously or are currently taking ART and 
what regimen, current and previous pregnancies, payer 
(eg, government-funded programme, private insurance/
benefits, clinical trial), cost and other demographic 
data as provided, such as drug use, sexual orientation, 
sex trade work, disabilities, co-infections, experience of 
violence, history of mental health issues, among others) 
and evaluative methods (eg, standard gamble, survey 
techniques, and semistructured interview).
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Reporting across studies were variable, with some 
study authors reporting mostly direct quotations, and 
others reporting author-generated interpretations or 
themes and rarely reporting direct quotations. Data 
were extracted from qualitative studies using thematic 
synthesis.27 Quotations and descriptions of findings in 
the abstract and results of studies were considered. We 
extracted all quotations and author-identified themes 
that were relevant to taking ART, for example, concern 
over toxicity of medication and concern about transmis-
sion of HIV. We excluded factors that would be similar 
for either medication regimen, for example, access 
to services, experiences or concerns about intimate 
partner violence. Relevant quotations were coded and 
categorised to identify common themes. Themes were 
summarised narratively in a table. Quotes that were 
most illustrative of identified themes were reported 
in the description of the themes. We also extracted 
the funding source of the study and authors’ conflicts 
of interests, when reported. We did not pre-specify 
important subgroups.
Incorporation into BMJ rapid recommendations
In the BMJ Rapid Recommendations project, a panel 
of clinicians, researchers, methodologists and patient 
representatives create rapid and trustworthy recom-
mendations22 (box 1). To provide the panel with best 
current evidence on cART treatment alternatives for all 
patient-important outcomes, a linked systematic review 
on safety and efficacy was performed that summarised 
outcomes related to maternal and child health in preg-
nant women living with HIV or HIV and hepatitis B.24 
The BMJ Rapid Recommendation panel considered the 
evidence from the systematic review on relative effects 
as well as evidence from this review on women’s values 
and preferences to make recommendations using 
the  Grading of Recommendations, Assessment, Devel-
opment and Evaluation (GRADE) framework.22 28 In 
addition, results were used to inform the online consul-
tation decision aids generated from the evidence 
summary supporting this BMJ Rapid Recommenda-
tions, available online through MAGICapp (http://
www. magicapp. org) (box 2).
results
Study characteristics
From 1596 unique citations, 96 proceeded to full-text 
review and 15 studies were eligible for inclusion (figure 1). 
All the included studies were qualitative and published in 
English, although 12 studies were conducted in another 
language. None of the studies evaluated women’s values 
and preferences when considering different ART regi-
mens. The included studies sought to identify barriers 
and facilitators to initiating, adhering to, or stopping ART 
(13 studies), uptake of HIV care and services (one study) 
and factors influencing fertility decisions in women 
living with HIV (one study). Five studies did not report 
a specific ART regimen. Geographic location varied, with 
the majority being low-income or middle-income coun-
tries (11 studies), most often in sub-Saharan Africa (six 
studies) (table 1). Three studies reported on feasibility 
and acceptability of Option B+.7–9 Authors rarely specified 
whether the included quotes from women about taking 
ARTs were referring to during pregnancy, after birth, or 
both. Twelve studies were funded by government-related 
grants and three did not report funding source29–31: none 
were industry sponsored. Most studies did not report 
conflicts of interest (11 studies);8 9 29–36 the rest stated 
authors had no competing interests.7 37–40
study quality
Studies were generally of moderate methodological quality 
(see online supplementary appendix 4). Most included 
fewer than 50 participants (seven studies).30–34 36 37 The 
most common sampling strategy was convenience (eight 
studies).29–32 35–37 40 Four studies reported response 
rates; 50% in one study37 and 90% or more in three 
others.32 33 38 No study discussed the relationship between 
the researcher and participants (reflexivity). Two studies 
described the researcher conducting the interviews.9 39 
No study discussed data saturation.
Values and preferences related to outcomes of Art
We identified six common themes in studies of the values 
and preferences of pregnant women living with HIV 
regarding ART (table 2).
box 1 Women living with hIV contributing to this 
systematic review
Three women living with HIV, two of whom had children after being 
diagnosed with HIV and another who is considering having children 
in the future, participated in the BMJ Rapid Recommendations panel. 
The community representatives received personalised training 
and support to optimise contributions throughout the guideline 
development process. These women provided substantive feedback to 
this systematic review protocol and helped guide interpretation of the 
results.
box 2 linked articles in this BMJ rapid 
recommendations cluster
Siemieniuk et al.23 Antiretroviral therapy in pregnant women living with 
HIV: a clinical practice guideline (co-submitted).
 ► BMJ Rapid Recommendation article
Siemieniuk et al.24 Antiretroviral therapy for pregnant women living 
with HIV or hepatitis B: a systematic review. (co-submitted).
 ► A systematic review of antiretroviral therapies in pregnant women
MAGICapp
 ► Expanded version of the evidence with multilayered 
recommendations, evidence summaries and decision aids for use 
on all devices.
 ► https://www.magicapp.org/public/guideline/VLpr5E
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Desire to reduce vertical transmission risk
Nine studies reported that reducing the risk of vertical 
transmission is extremely important to most women. 
Many women expressed a strong desire for having 
a child without HIV. One woman described “I knew 
taking them [ARTs] each day was something else, but I 
really wanted to give birth to a normal child without a 
disease and that was so precious a thing to me”.8 Women 
who already had a child without HIV expressed desire 
to take ARTs again, as one woman said “My last baby 
is fine, and I would hope that this baby is the same”.39 
Taking ARTs to protect the unborn child appeared 
universally important, although findings from at least 
one study suggested that this may not always be the 
most important factor, as summarised by investigators: 
“side effects posed a high cost to women, and they had 
to weigh the future benefit of ART for their child with 
their immediate health and economic needs”.9
Desire for child to be healthy
Several studies reported that a women’s concern about 
their child’s health, either before or after birth, was 
important to them, without specifying exactly what it 
means to be healthy (five studies). For example, investi-
gators stated “several women expressed that their babies’ 
welfare is what spurred them to take greater responsi-
bility for taking their medications as prescribed […] their 
concerns were often focused on health of the unborn 
child”.32 Two studies suggested that at least some women 
had concerns about long-term adverse effects from ART on 
their child: ‘concerns for the baby, however, went beyond 
having a safe and successful delivery and included fears 
about long-term effects’.36 At least one woman expressed 
her concern that there are “no long-term studies on [the 
risk of AZT] either, as to what, if anything happens to chil-
dren from having taken that toxic a drug in their system 
during their [mothers’] pregnancy”.39
Concern about ART side effects to the fetus
Many women are concerned about the possibility of side 
effects from ART on their fetus (eight studies). This was 
usually reported by women in general terms, such as “antiret-
rovirals are quite strong drugs which can ruin the foetus”.31 
One study, however, reported that miscarriage was a specific 
concern.33 Although some women were concerned about 
the possibility of side effects on their fetus, many still chose 
to use ART during pregnancy, as summarised by study 
investigators: “Accepting treatment for the sake of the 
baby, however, did not free women from worry that it might 
adversely affect their unborn children”.34
Desire for oneself to be healthy
In five studies, women revealed a desire to be healthy. 
For some, this desire was about their general health, as 
Figure 1 PRISMA study flow diagram. ART, antiretroviral therapy; PRISMA, Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses.
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one woman stated ‘it has given me strength, not getting 
sick often. Working like other people work and the body 
isn’t weak’.7 In another example, health was important to 
the woman in order to care for the child; “I don’t want 
someone else to have to take care of my child because I 
can’t and that’s what worries me the most…it’s motivated 
me to be more responsible”.32
Concern about ART side effects to oneself
Side effects were a commonly reported reason for not 
starting or stopping ARTs (10 studies). For some women, 
these side effects impacted their ability to provide for 
their family. One investigator noted: “The effects of ART 
did not match women's expectation that medicine would 
treat illnesses and make them feel better. When women 
compared their health before and after taking ART, they 
saw a marked decline, often feeling sicker, weaker and 
unable to carry on with daily tasks”.9 However, side effects 
were not always a strong enough deterrent to stop taking 
ART. Another investigator commented “While most 
women continued ART despite side effects, some stopped 
because side effects made them feel worse than before 
they started treatment”.8
Burden of treatment
None of the studies offered all women multiple ART 
dosing times per day. Pill burden was indirectly consid-
ered from reports of reasons for non-adherence, such 
as forgetting to take medication, being too busy to take 
medication due to work or other duties and sleeping 
through the dose time.29 32 Only two studies mentioned 
these themes, and in neither did pill burden appear 
to be a major factor when considering ART during 
pregnancy.
There was no statement from any women about cost 
being an issue. Cost of drugs was not considered a major 
factor because ART is supplied free of charge in most 
programmes from studies in this review (table 1). Some 
studies report on the cost of using service/transportation 
instead, which is not expected to differ between ART regi-
mens.8 33 40 One study reported that they included women 
who attended private clinics, but did not report on costs.7
dIsCussIOn
Principal findings
This is the first systematic review of the values and prefer-
ences of women living with HIV related to the choice of 
Table 2 Themes addressed in qualitative studies of the values and preferences about antiretroviral therapy in women living 
with HIV
Child health Maternal health
Burden of 
treatment
Facilitator Barrier Facilitator Barrier Barrier
Desire to 
reduce 
transmission
Desire for child 
to be healthy
Concern about ART 
side effects
Desire to be 
healthy
Concern about 
ART side effects Pill burden*
Ciambrone 200732 ✓ ✓ ✓ ✓
Ekama 201229 ✓ ✓ ✓ ✓
Ferguson 201437 ✓
Katiyari 201640 ✓
Katiyari 20167 ✓
Kim 20168 ✓ ✓ ✓
Kohler 201438 ✓† ✓†
Mawar 200730 ✓
McDonald 201134 ✓ ✓ ✓
Ndlovu 200931 ✓ ✓
Richter 200236 ✓ ✓ ✓ ✓
Siegel 200139 ✓ ✓ ✓ ✓
Sowell 200135 ✓ ✓† ✓†
Stinson 201233 ✓ ✓ ✓
Zhou 20169 ✓ ✓ ✓
*Pill burden: reports of forgetting or too busy to take medication, as well as sleeping through medication dosing time, were considered pill 
burden.
†Authors wrote that women were concerned about harm to mother and/or child but did not provide more detail.
ART, antiretroviral therapy.
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ART. Although we did not identify any reports with direct 
evidence regarding any two ART regimens, there were 
several studies that were indirectly informative to the 
study question by reporting key factors for the decision to 
use or to not use ART around the time of pregnancy. Most 
studies did not specify the ART regimen considered, and 
it is unclear whether only one regimen was available for 
those women, and if they were given any choice.
We identified six factors as being important to pregnant 
women living with HIV when considering ART: a desire 
to reduce vertical transmission, a desire for child to be 
healthy, concern about side effects to the fetus, a desire 
for oneself to be healthy, concern about side effects and 
pill burden. There were no formal questions regarding 
prioritisation, but several quotes suggested that women 
were balancing the desirable and undesirable conse-
quences of taking ART when making their decisions, for 
example, reducing vertical transmission and side effects. 
Many women valued the personal health benefit to taking 
ARTs during pregnancy, but some found the side effects 
hard to tolerate and impacted their ability to work and 
provide for their family. Pill burden was only indirectly 
identified as a potential concern based on reports of 
non-adherence relevant to timing of medication regimen 
in two studies. Because pill burden did not appear to 
be a major concern in most studies and only indirectly 
mentioned in two others, it may be less important than 
the other factors in this population.
strengths and weaknesses
Our review has several strengths compared with previously 
published evidence. First, we followed the MOOSE guide-
lines, and prospectively registered our protocol. Second, 
we performed a recent comprehensive search using a 
validated filter for values and preferences, and did not 
limit findings to a particular study design nor language 
of publication. Third, we selected studies, extracted data 
and conducted quality assessment of primary studies inde-
pendently and in duplicate. Fourth, the themes we iden-
tified in our study were consistent with what the women 
on the linked Rapid Recommendation guideline panel 
considered most important for decision-making.23
There are some limitations to the current evidence. 
First, most studies identified additional factors that influ-
enced initiation, adherence and/or stopping ART, which 
were out of scope for this review. It is challenging to sepa-
rate factors that may influence the choice of ART regimen, 
as personal, community and health service issues are 
often intertwined.8 11 Second, we included three studies 
that addressed Option B+, where women are advised to 
start cART as soon as their status is identified during preg-
nancy, and continue for life. As such, some of the iden-
tified factors influencing cART adherence may not have 
been related to the pregnancy period but rather lifelong 
therapy. However, identified themes in Option B+ studies 
appeared to be consistent with studies limited to the preg-
nancy period. Third, there may be important individual 
differences, as well as geographic and temporal trends 
in weighing factors, that were not observed. At least one 
recent systematic review compared individual, commu-
nity and healthcare system barriers and facilitators to 
ART adherence in sub-Saharan Africa before and after 
2008, and found that they were consistent.11 The iden-
tified barriers and facilitators may not be generalisable 
to all ART regimens. Contextual factors (interpersonal, 
programme-level) may have a greater influence in some 
settings compared with others.
Context in relation to the body of literature
Several related systematic reviews have been published 
on barriers and facilitators to ART initiation and 
adherence as well as uptake of perinatal HIV services 
among women living with HIV who are pregnant or 
considering pregnancy.11–14 Factors that have been 
associated with better adherence or service uptake 
include disclosed status, higher education level, 
knowledge of vertical transmission prevention and 
ART, care in an urban/district setting rather than a 
rural one, older age, support in care (by healthcare 
workers, partners, family and community) and partic-
ipation in health services. Factors associated with 
worse adherence or service uptake include denial 
of HIV, stigma, substance abuse, negative attitudes/
treatment from healthcare workers, scheduling issues 
(eg, job demands), food and water availability, lost/
stolen medication, under-resourced clinics (long wait 
times, lack of trained staff, among others), service 
provider being far from home and cost (transpor-
tation, payment for clinic/drugs if not govern-
ment-provided). Studies provide inconsistent results 
as to whether religion represents a barrier or a facil-
itator, which is likely to depend on the individual 
and the setting. All of these factors were not relevant 
to a woman’s choice of which ART regimen to use 
after having already decided to initiate ART, but are 
important to the decision of whether or not to start 
ART and for long-term medication adherence.
unanswered questions and future research
We did not identify any studies about women being 
given the choice of ART alternatives, or about prioriti-
sation of outcomes related to taking ART. For example, 
none addressed how important once or twice dosing 
per day is to women. In most reported settings, the 
major issue affecting ART initiation was access to any 
treatment, which inherently makes choice between 
therapeutic alternatives and dose scheduling a lower 
priority.
No study commented on participant–researcher 
reflexivity, despite its importance in qualitative 
research.41 Future research should give more consider-
ation to how the interviewer or research team impacts 
what women report. In addition, subsequent studies 
should consider sampling participants until data satu-
ration has been reached, and discussing how this was 
done.42
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Future research should focus on ways to effec-
tively implement shared decision-making in different 
settings, including high and low resourced settings. It is 
important to learn when and how to have these conver-
sations, in what context and with what impact on reten-
tion to care, in a way that most effectively empowers 
women, especially with women who are diagnosed 
during pregnancy.
COnClusIOns
Many women living with HIV probably consider the health 
of their child as the most important factor for taking ART 
during pregnancy, but have to balance this with their own 
health. Pill burden and medication complexity appears 
to be a lower priority for most women. There was vari-
ability in whether women chose to take ART or not and in 
the factors that women identified as being important to 
them. An individualised women-centred approach, such 
as shared decision-making, should be emphasised for 
empowering women to make choices that best suit their 
own values and preferences and accommodate into their 
context.
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